We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at ...

Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression ...

Johnson & Johnson (NYSE:JNJ) is advancing psychedelic medicine with Spravato (esketamine), an FDA-approved nasal spray for treatment-resistant depression and acute suicidal ideation. Since its ...

Jason Najum talks to Srinivas Rao, CEO of Atai Life Sciences, a biotech company focused on mental health and psychedelic compounds.

Stifel has initiated Compass Pathways (NASDAQ:CMPS) with a buy rating saying that stakeholders are starting to agree there is ...

Escalating concerns over impending tariffs and President Trump's foreign policies have fueled uncertainty and instability in ...

Speaker Mike Johnson (R-La.) asked for prayers as he prepares to bring the House’s budget reconciliation resolution, the vehicle for President Trump’s ambitious legislative agenda, for a floor ...

Johnson & Johnson was founded over 125 years ago in the year 1886. However, it wasn't until 1959 – 73 years and two major acquisitions later – that J&J developed its significant presence in ...

Johnson & Johnson’s Consumer Health segment reported a revenue of $14.6 billion in the Full-Year 2021. It is projected that, following the separation, Kenvue will generate sales in over 100 ...

Washington — The House adopted a budget proposal on Tuesday that paves the way for implementing President Trump's legislative agenda, handing a major victory to House Speaker Mike Johnson who ...